Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia

被引：0
|
作者：
Mikkel Krogh-Madsen
Brendan Bender
Morten Krogh Jensen
Ove Juul Nielsen
Lena E. Friberg
Per Hartvig Honoré
机构：
[1] University of Copenhagen,Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences
[2] Uppsala University,Department of Pharmaceutical Biosciences, Pharmacometrics Research Group
[3] Herlev Hospital,Department of Haematology L
[4] Rigshospitalet,124
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Cytarabine; Etoposide; Daunorubicin; Population pharmacokinetics; NONMEM; Acute myeloid leukemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1155 / 1163
页数：8
相关论文
共 50 条
  • [31] Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
    Blair, Hannah A.
    DRUGS, 2018, 78 (18) : 1903 - 1910
  • [32] FLAG and Etoposide as Salvage Treatment in Acute Myeloid Leukemia
    Papadantonakis, Nikolaos
    ACTA HAEMATOLOGICA, 2020, 143 (05) : 403 - 404
  • [33] Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia
    Trifilio, Steven M.
    Rademaker, Alfred W.
    Newman, Diane
    Coyle, Katherine
    Carlson-Leuer, Katrin
    Mehta, Jayesh
    Altman, Jessica
    Frankfurt, Olga
    Tallman, Martin S.
    LEUKEMIA RESEARCH, 2012, 36 (04) : 394 - 396
  • [34] Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience
    Onec, Birgul
    Okutan, Harika
    Albayrak, Murat
    Can, Esra Saribacak
    Aslan, Vedat
    Koluman, Basak Unver
    Kosemehmetoglu, Ozge Soyer
    Albayrak, Aynur
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (05) : 1105 - 1111
  • [35] Etoposide and cytarabine as an effective and safe cytoreductive regimen for relapsed or refractory acute myeloid leukemia
    Nair, G.
    Karmali, R.
    Gregory, S. A.
    Shammo, J. M.
    Fung, H. C.
    Jimenez, A.
    Venugopal, P.
    Larson, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Venetoclax Combining with Homoharringtonine,Daunorubicin and Cytarabine (HAD) As Induction Treatment in Newly Diagnosed Adult Acute Myeloid Leukemia Patients
    Yan, Zhangsong
    Li, Yang
    Zhang, Bin
    He, Jinsong
    Li, Jiesi
    Wei, Shuning
    Wang, Qi
    Li, Qiuling
    Hu, Bo
    Liu, Kaiqi
    Mi, Yingchang
    BLOOD, 2023, 142
  • [37] FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
    Krauss, Aviva C.
    Gao, Xin
    Li, Liang
    Manning, Michael L.
    Patel, Paresma
    Fu, Wentao
    Janoria, Kumar G.
    Gieser, Gerlie
    Bateman, David A.
    Przepiorka, Donna
    Shen, Yuan Li
    Shord, Stacy S.
    Sheth, Christopher M.
    Banerjee, Anamitro
    Liu, Jiang
    Goldberg, Kirsten B.
    Farrell, Ann T.
    Blumenthal, Gideon M.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2685 - 2690
  • [38] Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia
    Bewersdorf, Jan Philipp
    Goshua, George
    Patel, Kishan K.
    Shallis, Rory M.
    Podoltsev, Nikolai
    Huntington, Scott F.
    Zeidan, Amer M.
    BLOOD, 2021, 138
  • [39] A Retrospective Comparison of Hypomethylating Agent in Combination with Venetoclax Versus Liposomal Daunorubicin and Cytarabine in Frontline Treatment of Acute Myeloid Leukemia
    Maher, Keri R.
    Bouligny, Ian M.
    BLOOD, 2021, 138
  • [40] A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia
    Masaoka, T
    Ogawa, M
    Yamada, K
    Kimura, K
    Ohashi, Y
    SEMINARS IN HEMATOLOGY, 1996, 33 (04) : 12 - 17
12345